Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CUE with free AI briefings, catalyst countdowns, and dilution alerts.

CUE · Cue Biopharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 2.6 months of cash at its recent burn rate (Jun 30, 2026 balance sheet), a shelf registration filed Mar 16, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 months of cash or less, 51% sold new shares within three months and 73% were lower 60 trading days later (median -24%). How we know
$17.4M Cash on Hand
2.6mo Cash Runway
Follow CUE by email Get an email when CUE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CUE, unsubscribe in one click. Privacy

📣 What CUE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
HPV16 E7-specific HLA-A*02:01-restricted… Head and Neck Squamous Cell Carcinoma Phase 2 · NCT07172256 Recruiting

Also used in these trials (approved or third-party drugs, not CUE's own candidates): Pembrolizumab, WT1-targeted IL-2-based Fusion Protein CUE-102.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CUE holds $17.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $20M/quarter from operations, an estimated runway of 2.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CUE files for a raise →

👥 Who Owns CUE

Insiders 12.1% Institutions (66 holders) 33.9% Public and other holders 54%
HolderTypeShares% of sharesAs of
Cormorant Asset Management, LP Institution (13G, 5%+) 791,377 9.47% 2026-09-30
Shao-Lee Lin
Chief Executive Officer, Director · +1.01M options
Insider 694,908 8.31% 2026-10-12
Bleichroeder LP Institution (13G, 5%+) 663,009 7.93% 2026-09-30
BALYASNY ASSET MANAGEMENT L.P. Institution (13G, 5%+) 427,231 5.11% 2026-09-30
Sumita Ray
Chief Legal Compliance Officer · +36,393 options
Insider 116,701 1.40% 2026-10-12
Michael Vincent Meluzio
VP, Prin. Accounting Officer · +27,295 options
Insider 47,817 0.57% 2026-10-12
Dominique Christian Borie
Chief Medical Officer · +63,000 options
Insider 31,500 0.38% 2026-07-13
Pasha Sarraf
Director · +24,400 options
Insider 29,195 0.35% 2026-07-09
James M Ahlers
Chief Financial Officer · +51,000 options
Insider 25,500 0.31% 2026-07-30
Viola Mong Meehan
Director · +1,626 options
Insider 21,800 0.26% 2026-07-09
Daniel A. Camardo
Director · +1,626 options
Insider 21,800 0.26% 2026-07-09
Pamela Garzone
Director · +24,400 options
Insider 18,900 0.23% 2026-07-09

Share count 8,359,523 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CUE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CUE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.